Teleflex Inc TFX
Teleflex Inc (NYSE: TFX) is a medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Aug 6, 2026approval FDA granted BLA approval of EZPLAZ Freeze Dried Plasma (late July), the first freeze-dried plasma licensed by the FDA.
In late July, Teleflex received BLA approval from the U.S. Food and Drug Administration for EZPLAZ™ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA.
Filing - Aug 6, 2026positive Four-year follow-up of single-arm BIOMAG-I showed sustained long-term performance and favorable safety, with no new cardiac-related events between two and four years.
presented four-year follow-up data from the BIOMAG-I study demonstrating sustained long-term performance and a favorable long-term safety profile
Filing - Aug 6, 2026completed enrollment Enrollment completed ahead of schedule in randomized BIOMAG-II (Freesolve vs Xience DES); data readout expected late 2027.
completed enrollment, ahead of schedule, in the BIOMAG-II study, the first randomized controlled trial of Freesolve conducted outside the United States, positioning the Company for a data readout in late 2027
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.